GSK’s disinvestment of Chiron Behring to Bharat Biotech
Posted on16 Feb 2019
Tagsacquisition in pharma, Bharat Biotech, Chiron Behring Vaccines, disinvestment in pharma business, GSK, Hoechst AG
Comments0
Bharat Biotech’s recent plans to acquire Chiron Behring Vaccine Private Limited from GlaxoSmithKline Asia, is expected to boost the company’s rabies vaccine... Read More
Strides Shasun to disinvest India Generic Business; Eris Lifescience to acquire at 500 Crores
Eris Lifesciences has entered into a definitive agreement to acquire India branded generics business of Strides Shasun for an aggregate cash consideration... Read More
AstraZeneca outlicense lung disease to Mereo BioPharma
AstraZeneca is licensing exclusive rights of AZD9668 — an oral inhibitor of an enzyme called neutrophil elastase for lung disease to Mereo... Read More